Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 20/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 14/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2128699 | 0.81 | DGAT1 (0.53) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL8992167 | 0.81 | DGAT1 (0.55) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL8992142 | 0.77 | DGAT1 (0.54) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL28504523 | 0.73 | USP30 (0.34) | DGAT1 | |
| SCHEMBL17841503 | 0.73 | F2 (0.33) | — | |
| SCHEMBL28509577 | 0.70 | NNMT (0.33) | — | |
| SCHEMBL23339907 | 0.68 | DGAT1 (0.67) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL20519764 | 0.67 | NNMT (0.33) | — | |
| SCHEMBL2126247 | 0.66 | DGAT1 (0.65) | DGAT1SOAT1FAAHCHRM2DGAT2 | |
| SCHEMBL14745974 | 0.66 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| US-8188092-B2 | Substituted pyrazines as DGAT-1 inhibitors | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | ASTRAZENECA AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324068-A1 | CHEMICAL COMPOUNDS 785 | GPBAR1, DGAT1, GPR119 | DGAT1 2/4885SOAT1 11/4885FAAH 829/4885 |
| US-20120289520-A1 | CHEMICAL COMPOUNDS 785 | DGAT1, DGAT2, SLC5A1 | DGAT1 1/4885SOAT1 9/4885FAAH 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.